In a recent study by Festuccia et al. ozarelix, a decapeptide GnRH antagonist, significantly restores cell sensitivity to human recombinant tumor necrosis factor-related apoptosis inducing ligand (TRAIL)-mediated apoptosis in androgen-independent prostate cancer cell lines DU145 and PC3 (~60–70 % apoptotic cells; 20 ng/mL ozarelix plus 500 ng/mL TRAIL) versus cells treated with TRAIL alone (~10 % apoptotic cells; 500 ng/mL TRAIL) [66]. The gene discussed is GNRH1; the disease is Familial prostate cancer.